Clinical Trial: A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas

U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT06219356) titled 'A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas' on Dec. 22, 2023.

Brief Summary: Study GLB-002-01 is a first-in-human (FIH), phase 1, open-label, dose escalation and expansion clinical study, the purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-002 monotherapy in participants with relapsed or refractory Non-Hodgkin lymphomas (R/R NHL).

Study Type: Interventional

Condition: Non-Hodgkin Lymphoma

Intervention: Drug: GLB-002

Administered orally according to the assigned treatment schedule.

Other Name: GLB-A06...